Clinical & Molecular Biomedicine (CMB) is an international, peer-reviewed, open-access journal that publishes research connecting molecular discoveries with clinical applications. The journal provides a platform for scientists, clinicians, and biomedical researchers to share work that improves understanding, diagnosis, and treatment of human disease through translational medicine.

CMB promotes interdisciplinary research bridging basic molecular science and clinical medicine. It welcomes studies in translational medicine, molecular and cellular biology, clinical biochemistry, genomics and epigenetics, proteomics and metabolomics, microbiome research, molecular oncology, neurobiology, biomarker discovery, drug discovery and resistance, gene and cell therapy, precision medicine, and immunology and vaccinology.

The journal is particularly interested in studies that explain molecular mechanisms underlying human disease and show how those findings can support clinically meaningful outcomes. This includes work on disease-associated genetic and epigenetic variation, molecular biomarkers, metabolic pathways, therapeutic targets, treatment resistance, and personalized therapeutic strategies.

CMB also welcomes submissions that combine experimental, computational, and clinical approaches rather than treating those areas separately. Studies that integrate molecular data with clinical relevance, emerging biomedical technologies, or translational interpretation are especially well suited to the journal.

Across all article types, the journal values scientific rigor, ethical conduct, reproducibility, and clear relevance to molecular and clinical biomedicine. The overall aim is to publish work that not only advances biomedical knowledge, but also helps move research findings toward practical benefit in diagnosis, therapy, and patient care.

The mission of CMB is to move discoveries from bench to bedside by accelerating the development of diagnostics, therapeutics, and personalized medicine. The journal is committed to rigorous, fair, and timely peer review by experts in the field.

CMB follows high standards of research ethics, data reporting, and reproducibility so that published work is both scientifically sound and clinically meaningful.

CMB accepts original research articles, review articles, short communications, case reports, methods and protocols, and letters to the editor.

This journal follows a single anonymized review process. Every submission is first assessed by the editors for suitability, scope, originality, ethical compliance, and general quality.

If a manuscript is considered suitable, it is typically sent to at least two independent reviewers for expert assessment of scientific quality. Editorial decisions may be accept, minor revision, major revision, or reject, and the Editor-in-Chief has final authority over all editorial decisions.

Authors must ensure that the manuscript is original, unpublished, and not under consideration elsewhere in print or electronic form. One corresponding author must be clearly designated and all required files must be uploaded successfully at submission.

A cover letter must accompany every submission. It should describe the scope, importance, and novelty of the manuscript, confirm originality and exclusive submission to CMB, disclose competing interests, acknowledge funding and contributions, and may suggest reviewers or request the exclusion of up to five reviewers.

Submission is completed through the journal's online manuscript system. Authors should provide editable source files at every submission and revision stage, and author contribution and competing-interest information must also be supplied through the submission interface.

CMB follows publication ethics guidance from COPE, ICMJE, and WAME. Authors must submit original work, avoid plagiarism or duplicate publication, report data accurately, cite sources properly, and provide ethical approval for human and animal research where relevant.

Submission to CMB also implies that the work has not been published previously except in allowable forms such as preprints, abstracts, lectures, academic theses, or registered reports, that it is not under consideration elsewhere, and that publication is approved by all authors and relevant institutions.

Authorship should follow widely accepted international criteria such as those recommended by ICMJE. All authors should have contributed substantially to the study design, execution, analysis, or interpretation, participated in drafting or critically revising the manuscript, approved the final version, and agreed to be accountable for the work.

CMB requires an Author Contribution Statement using clear role descriptions and encourages use of CRediT terminology. Requests to add, remove, or reorder authors after submission must be justified in writing and approved by all authors, and such changes are generally not permitted after acceptance.

Generative AI tools cannot be listed as authors. If AI tools are used for language editing, drafting assistance, or similar support, that use must be disclosed clearly in the manuscript, and human authors remain fully responsible for accuracy, integrity, and originality.

A dedicated Statements and Declarations section should be included after the references. Authors must disclose competing interests and all funding sources, and should explain the role of the funder in study design, data collection, data analysis and interpretation, manuscript preparation, and the decision to submit.

The journal encourages inclusive and respectful language and recommends that authors avoid biased or exclusionary wording. Research involving humans, animals, or eukaryotic cells should consider sex- and gender-based analyses where relevant and explain how those factors were addressed or why such analyses were not conducted.

CMB maintains a strict policy against plagiarism, duplicate publication, data fabrication, falsification, image or dataset manipulation, and unethical research practices. All manuscripts are screened for originality, and serious concerns may lead to rejection, correction, expression of concern, retraction, or notification of institutions and funding bodies in line with established ethical guidance.

CMB requires editable source files for the manuscript text, figures, tables, and graphical elements. Manuscripts should be submitted in .doc, .docx, or .tex format; PDF files are not accepted as source files.

Manuscripts should be prepared in Word using a normal plain font such as 12-point Times Roman with 1.5 line spacing. Use italics for emphasis, automatic page numbering, the table function for tables, and an equation editor or MathType for equations.

A standard manuscript should include a title page, abstract, keywords, introduction, materials and methods, results, discussion, conclusions, funding, acknowledgements, references, figure legends, and tables and figures.

The title page should include a concise and informative article title, the full names of all authors, author affiliations, corresponding author details, and any present or permanent address information where applicable. Affiliations should include department or institution name, full postal address, country, and email where available.

The abstract should stand alone and should usually be 150 to 250 words covering background, methods, key results, and conclusions. Authors should provide four to six keywords for indexing purposes.

Tables must be editable, clearly captioned, numbered in the order they appear, and not submitted as images. Figures should be supplied as separate high-resolution files as well as placed appropriately within the manuscript or at its end.

Vector graphics should preferably be submitted as EPS or PDF with embedded fonts, photographs and halftone images as TIFF, and other formats such as JPG or PNG are acceptable if they meet the journal's resolution requirements. Authors should use clear lettering, consistent fonts, proper scale bars where needed, and figure captions in the manuscript file rather than inside the image.

Authors are encouraged to submit supplementary material that strengthens the scientific record, including extended datasets, additional figures or tables, high-resolution images, software, protocols, and relevant multimedia files. Supplementary files must be cited in the manuscript, submitted together with the original submission, and supplied with clear and descriptive captions.

Video and multimedia files should be referenced in the manuscript, named clearly, provided in commonly accepted formats, and accompanied by a representative still image and a concise description.

CMB strongly supports open, transparent, and reproducible research practices. Authors are encouraged to deposit research data in recognized public repositories, cite and link datasets within the manuscript, and provide enough methodological and contextual information for others to interpret and reuse the data.

A Data Availability Statement is encouraged and should explain where and how the data can be accessed or why access is restricted. Footnotes should be used sparingly, acknowledgements should appear before the references, and a detailed Author Contributions statement using CRediT should be provided for all submissions.

All references cited in the manuscript must appear in the reference list, and all listed references must be cited in the text. References cited in the abstract should also be included in full, and authors should ensure that every reference is accurate and complete at submission.

CMB uses a numbered citation style with references cited in square brackets and numbered in the order they first appear. When previously published figures, tables, or text excerpts are reused, authors must obtain written permission from the copyright holder before submission and provide documented evidence of that permission.

All research involving human participants, human data, animals, or animal-derived materials must follow recognized ethical standards. Authors must include ethics approval statements in the manuscript and identify the approving committee, together with the relevant approval or reference number where applicable.

For human studies, authors must confirm that informed consent was obtained from participants or their legal guardians. If a manuscript contains identifiable individual information, images, or case details, explicit consent to publish must also be obtained.

Clinical trials submitted to CMB should comply with Good Clinical Practice standards and be prospectively registered in a recognized public registry before the first participant is enrolled. Trial registration details should be reported in both the abstract and methods section, and authors should explain any deviation from the registered protocol.

For clinical trials and evidence syntheses, authors should follow appropriate reporting guidance such as CONSORT, STARD, PRISMA, and SPIRIT. Systematic reviews and meta-analyses should present a transparent search strategy, eligibility criteria, study selection process, risk-of-bias assessment, and synthesis methods, and should be accompanied by a PRISMA flow diagram and checklist.

Authors are encouraged to submit manuscripts in clear and grammatically correct English. Upon acceptance, the corresponding author receives a publishing agreement, and authors retain copyright while publishing under the Creative Commons Attribution (CC BY) license.

All articles in CMB are published through a fully open-access model with no article processing charge. This supports immediate and unrestricted access, broader visibility, compliance with funder requirements, and equitable access to scientific knowledge.

The proof stage is intended for correcting typesetting, formatting, or conversion errors and for checking the overall accuracy of the manuscript. Substantial changes are not normally allowed at this stage without editorial approval.

Accepted articles are published online shortly after corrected proofs are received and are citable through their DOI. To preserve the integrity of the scholarly record, the journal may issue errata, corrigenda, expressions of concern, or retractions where necessary, and serious research misconduct is handled in accordance with internationally recognized ethical standards.